---
schema_version: "secwatch.filing_event.v1"
accession: "0001528287-22-000011"
form_type: "8-K"
ticker: "NPCE"
cik: "0001528287"
company_name: "NeuroPace Inc"
filed_at: "2022-05-12T23:59:59+00:00"
generated_at: "2026-06-25T18:14:50.773886+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# NeuroPace Q1 revenue $11.4M, net loss widens to $11.5M; guides FY2022 revenue $45-48M

## Summary
- Total revenue $11.4M (+2% YoY); initial implant rev $8.8M (+9%); replacement rev $2.6M (-16%).
- Net loss widened to $11.5M from $8.8M; operating expenses $18.0M vs $12.4M.
- Gross margin 73% vs 76% due to higher costs and COVID disruptions; cash $103.2M.
- FY2022 guidance: revenue $45-48M, initial implants $39-42M, opex $74-76M.
- On track to enroll first patients in NAUTILUS trial for generalized epilepsy expansion mid-2022.

## SEC filing metadata
- accession: 0001528287-22-000011
- form_type: 8-K
- ticker: NPCE
- cik: 0001528287
- company_name: NeuroPace Inc
- filed_at: 2022-05-12T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000011/0001528287-22-000011-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1528287/000152828722000011/npce-20220512.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001528287-22-000011
- JSON: https://secwatch.observer/filing/0001528287-22-000011.json
- Plain text: https://secwatch.observer/filing/0001528287-22-000011.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.